Anion Gap in the Elderly

Why older adults distort the gap

The anion gap in older adults is subject to two opposing forces. On one side, age-related loss of renal mass lowers glomerular filtration and retains phosphate, sulfate, and organic anions — pushing the gap upward, exactly as it does in the broader anion gap in CKD population. On the other side, the high prevalence of hypoalbuminemia in the elderly (from poor nutrition, chronic inflammation, or nephrotic syndrome) suppresses the dominant "unmeasured anion" and pulls the calculated gap downward by roughly 2.5 mEq/L for every 1 g/dL of albumin below 4.0.

The net effect is that an older patient's measured anion gap frequently looks deceptively normal even when significant metabolic acidosis is present. The single most important interpretive habit in geriatric acid-base analysis is therefore to always compute the albumin-corrected gap before declaring the result normal. The anion gap calculator handles this correction; doing it by hand, use AG_corrected = AG + 2.5 × (4.0 − albumin).

Polypharmacy and the anion gap

Older patients take more medications, and several of the most common culprits of drug-induced high anion gap acidosis are mainstays of geriatric prescribing. The two highest-yield drugs to ask about are metformin and acetazolamide.

• Metformin — the first-line oral hypoglycaemic in type 2 diabetes — inhibits mitochondrial complex I and can precipitate severe lactic acidosis when renal clearance fails, especially in the setting of acute kidney injury, hypoperfusion, or contrast nephropathy (Kraut & Madias, CJASN).
• Acetazolamide, used for glaucoma and altitude/mountain sickness, is a carbonic anhydrase inhibitor that causes bicarbonaturia, hyperchloremia, and a normal-anion-gap (hyperchloremic) metabolic acidosis — the gap stays normal while bicarbonate falls.
• Propylene glycol, a vehicle in many IV preparations (lorazepam, phenytoin), is converted to lactate and can widen the gap in the ICU setting.
• Salicylates and chronic toxin exposure remain relevant at any age.

Metformin-associated lactic acidosis (MALA)

MALA is the classic example of polypharmacy-driven high anion gap acidosis in the elderly. The absolute incidence is low, but the case fatality rate is high — often quoted at 30–50% (Kraut & Madias, CJASN; LITFL Toxicology). The risk rises steeply with accumulating metformin levels, which occur when renal function acutely declines in a patient previously stable on the drug. Typical triggers include dehydration, sepsis, contrast-induced nephropathy, heart failure exacerbation, and perioperative hypoperfusion.

Clinically, the patient presents with severe lactic acidosis (lactate often > 10 mmol/L), a markedly elevated anion gap, hypotension, abdominal pain, and altered mental status. The arterial pH is frequently below 7.1. Management is supportive — fluids, vasopressors, and treatment of the precipitant — plus haemodialysis, which both clears metformin (a small, water-soluble molecule) and corrects the acidosis. Many centres initiate bicarbonate-based dialysis when the pH is profoundly depressed.

The preventive lesson is the more important one: reassess metformin at every renal-function checkpoint in older adults, hold it around iodinated contrast and major surgery, and consider its accumulation in any elderly patient who arrives with unexplained high anion gap metabolic acidosis.

Declining GFR and the baseline gap

Even without overt uremia, the gradual fall in GFR that accompanies normal aging raises the steady-state concentration of unmeasured anions. An older adult with a GFR of 45 mL/min may run a baseline anion gap a few mEq/L higher than a younger adult with the same albumin — the early signature of what becomes uremic acidosis in advanced kidney disease. Trending the gap against the patient's own prior values, rather than against a population reference, is the most reliable way to detect a new acid-base insult in an elderly patient with multiple chronic conditions.